Literature DB >> 19390910

Visual representation of National Institute of Allergy and Infectious Disease and Food Allergy and Anaphylaxis Network criteria for anaphylaxis.

Veena Manivannan1, Wyatt W Decker, Latha G Stead, James T C Li, Ronna L Campbell.   

Abstract

We present a user-friendly visual representation of The National Institute of Allergy and Infectious Disease and the Food Allergy and Anaphylaxis Network criteria so as to enhance recognition of anaphylaxis and active teaching and learning.

Entities:  

Year:  2009        PMID: 19390910      PMCID: PMC2672985          DOI: 10.1007/s12245-009-0093-z

Source DB:  PubMed          Journal:  Int J Emerg Med        ISSN: 1865-1372


Anaphylaxis is a potentially fatal acute systemic allergic reaction. It is becoming increasingly common. [1, 2] Multiple studies have shown that anaphylaxis is both under-recognized and under-treated. [3-5] Anaphylaxis is known to have varied presentations involving different organ systems. There are no universally accepted criteria for diagnosis of anaphylaxis. Lack of standardized diagnostic criteria has hampered diagnosis and management of anaphylaxis. The National Institute of Allergy and Infectious Disease and the Food Allergy and Anaphylaxis Network (NIAID/FAAN) organized an international symposium in 2005 at which new diagnostic criteria for anaphylaxis were proposed. Although not prospectively validated, these criteria provide physicians with a rapid and simplified means of making the diagnosis. Traditionally, the term ‘anaphylaxis’ referred to life-threatening manifestations of allergic reactions, such as respiratory distress or shock (anaphylactic shock) as manifested by hypotension or signs of hypoperfusion of critical organs. However, there is now a growing consensus that anaphylaxis is a systemic allergic reaction that typically involves more than one organ system but rarely can present with cardiovascular compromise as the only symptom. Therefore, the new criteria will capture broader presentations, encompassing less severe manifestations. The importance of recognition and diagnosis of mild presentations of anaphylaxis (for example, rash and vomiting after an allergen exposure) is underscored by a study by Pumphrey. [6] In this study of 139 fatalities due to anaphylaxis, 78% of deaths attributed to food allergy, and 82% of deaths attributed to venom allergy occurred in patients with no previous history of severe allergic reactions. These fatalities might have been prevented if the previous less severe presentations had been recognized and patients had been provided with self-injectable epinephrine and appropriate follow-up referrals. Table 1 shows the NIAID/FAAN criteria. [7] Patients are likely to have anaphylaxis if any one of the three criteria is present. It was believed that the criteria would “capture more than 95% of cases of anaphylaxis”. [7]
Table 1

National Institute of Allergy and Infectious Disease and Food Allergy and Anaphylaxis Network criteria for anaphylaxis

Anaphylaxis is likely when any one of these three criteria is fulfilled:
1. Acute onset of illness (minutes to several hours) with involvement of the skin, mucosal tissue, or both (e.g., generalized hives, pruritus or flushing, swollen lips, tongue, or uvula)
and at least one of the following:
 (a) Respiratory compromise (e.g., dyspnea, wheeze or bronchospasm, stridor, reduced peak expiratory flow, hypoxemia)
 (b) Reduced blood pressure or associated symptoms of end-organ dysfunction (e.g., hypotonia [collapse], syncope, incontinence)
2. Two or more of the following that occur rapidly after exposure to a likely allergen for that patient (minutes to several hours):
 (a) Involvement of the skin or mucosal tissue (e.g., generalized hives, itch or flush, swollen lips, tongue, or uvula)
 (b) Respiratory compromise (e.g., dyspnea, wheeze or bronchospasm, stridor, reduced peak expiratory flow, hypoxemia)
 (c) Reduced blood pressure or associated symptoms (e.g., hypotonia [collapse], syncope, incontinence)
 (d) Persistent gastrointestinal tract symptoms (e.g., crampy abdominal pain, vomiting)
3. Reduced blood pressure after exposure to known allergen for that patient (minutes to several hours):
 (a) Infants and children: low systolic blood pressure (age specific) or >30% decrease in systolic blood pressurea
 (b) Adults: systolic blood pressure <90 mmHg or >30% decrease from that person’s baseline

a Low systolic blood pressure for children is defined as <70 mmHg from 1 month to 1 year, < (70 mmHg + [2 × age]) from 1 to 10 years, and <90 mmHg from 11 to 17 years.

Modified from Sampson et al. [7]

National Institute of Allergy and Infectious Disease and Food Allergy and Anaphylaxis Network criteria for anaphylaxis a Low systolic blood pressure for children is defined as <70 mmHg from 1 month to 1 year, < (70 mmHg + [2 × age]) from 1 to 10 years, and <90 mmHg from 11 to 17 years. Modified from Sampson et al. [7] We present a user-friendly visual representation (Fig. 1) of the NIAID/FAAN criteria so as to enhance, not only recognition of anaphylaxis, but also active teaching and learning of these criteria among health-care providers. Increased recognition and diagnosis of anaphylaxis will hopefully lead to improved management and better outcomes in patients suffering from anaphylaxis.
Fig. 1

Visual representation of the National Institute of Allergy and Infectious Disease and Food Allergy and Anaphylaxis Network criteria for anaphylaxis

Visual representation of the National Institute of Allergy and Infectious Disease and Food Allergy and Anaphylaxis Network criteria for anaphylaxis
  7 in total

Review 1.  Lessons for management of anaphylaxis from a study of fatal reactions.

Authors:  R S Pumphrey
Journal:  Clin Exp Allergy       Date:  2000-08       Impact factor: 5.018

Review 2.  Epidemiology of anaphylaxis.

Authors:  Phil Lieberman
Journal:  Curr Opin Allergy Clin Immunol       Date:  2008-08

3.  Underreporting of anaphylaxis in a community emergency room.

Authors:  J S Klein; M W Yocum
Journal:  J Allergy Clin Immunol       Date:  1995-02       Impact factor: 10.793

Review 4.  Epidemiology of anaphylaxis: findings of the American College of Allergy, Asthma and Immunology Epidemiology of Anaphylaxis Working Group.

Authors:  Phil Lieberman; Carlos A Camargo; Kari Bohlke; Hershel Jick; Rachel L Miller; Aziz Sheikh; F Estelle R Simons
Journal:  Ann Allergy Asthma Immunol       Date:  2006-11       Impact factor: 6.347

5.  The etiology and incidence of anaphylaxis in Rochester, Minnesota: a report from the Rochester Epidemiology Project.

Authors:  Wyatt W Decker; Ronna L Campbell; Veena Manivannan; Anuradha Luke; Jennifer L St Sauver; Amy Weaver; M Fernanda Bellolio; Eric J Bergstralh; Latha G Stead; James T C Li
Journal:  J Allergy Clin Immunol       Date:  2008-11-06       Impact factor: 10.793

6.  Second symposium on the definition and management of anaphylaxis: summary report--Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium.

Authors:  Hugh A Sampson; Anne Muñoz-Furlong; Ronna L Campbell; N Franklin Adkinson; S Allan Bock; Amy Branum; Simon G A Brown; Carlos A Camargo; Rita Cydulka; Stephen J Galli; Jane Gidudu; Rebecca S Gruchalla; Allen D Harlor; David L Hepner; Lawrence M Lewis; Phillip L Lieberman; Dean D Metcalfe; Robert O'Connor; Antonella Muraro; Amanda Rudman; Cara Schmitt; Debra Scherrer; F Estelle R Simons; Stephen Thomas; Joseph P Wood; Wyatt W Decker
Journal:  J Allergy Clin Immunol       Date:  2006-02       Impact factor: 10.793

7.  Prescriptions for self-injectable epinephrine and follow-up referral in emergency department patients presenting with anaphylaxis.

Authors:  Ronna L Campbell; Anuradha Luke; Amy L Weaver; Jennifer L St Sauver; Eric J Bergstralh; James T Li; Veena Manivannan; Wyatt W Decker
Journal:  Ann Allergy Asthma Immunol       Date:  2008-12       Impact factor: 6.347

  7 in total
  10 in total

1.  Anaphylaxis after zoster vaccine: Implicating alpha-gal allergy as a possible mechanism.

Authors:  Cosby A Stone; Jonathan A Hemler; Scott P Commins; Alexander J Schuyler; Elizabeth J Phillips; R Stokes Peebles; John M Fahrenholz
Journal:  J Allergy Clin Immunol       Date:  2016-12-14       Impact factor: 10.793

Review 2.  Emerging Therapies in Anaphylaxis: Alternatives to Intramuscular Administration of Epinephrine.

Authors:  Brittany Boswell; Susan A Rudders; Julie C Brown
Journal:  Curr Allergy Asthma Rep       Date:  2021-03-05       Impact factor: 4.806

3.  Safety evaluation of the single-dose Ad26.COV2.S vaccine among healthcare workers in the Sisonke study in South Africa: A phase 3b implementation trial.

Authors:  Simbarashe Takuva; Azwidhwi Takalani; Ishen Seocharan; Nonhlanhla Yende-Zuma; Tarylee Reddy; Imke Engelbrecht; Mark Faesen; Kentse Khuto; Carmen Whyte; Veronique Bailey; Valentina Trivella; Jonathan Peter; Jessica Opie; Vernon Louw; Pradeep Rowji; Barry Jacobson; Pamela Groenewald; Rob E Dorrington; Ria Laubscher; Debbie Bradshaw; Harry Moultrie; Lara Fairall; Ian Sanne; Linda Gail-Bekker; Glenda Gray; Ameena Goga; Nigel Garrett
Journal:  PLoS Med       Date:  2022-06-21       Impact factor: 11.613

Review 4.  Immunogenicity Risk Assessment for an Engineered Human Cytokine Analogue Expressed in Different Cell Substrates.

Authors:  Paul Chamberlain; Bonita Rup
Journal:  AAPS J       Date:  2020-04-14       Impact factor: 4.009

5.  Drug-Induced Anaphylaxis Documented in Electronic Health Records.

Authors:  Neil Dhopeshwarkar; Aziz Sheikh; Raymond Doan; Maxim Topaz; David W Bates; Kimberly G Blumenthal; Li Zhou
Journal:  J Allergy Clin Immunol Pract       Date:  2018-06-30

6.  Frequency, distribution and immunologic nature of infusion reactions in subjects receiving pegloticase for chronic refractory gout.

Authors:  Leonard H Calabrese; Arthur Kavanaugh; Anthony E Yeo; Peter E Lipsky
Journal:  Arthritis Res Ther       Date:  2017-08-17       Impact factor: 5.156

7.  Identification of predictors for persistence of immediate-type egg allergy in Chinese children.

Authors:  Noelle Anne Ngai; Agnes Sze Yin Leung; Jonathan Chi Ho Leung; Oi Man Chan; Ting Fan Leung
Journal:  Asia Pac Allergy       Date:  2021-10-25

8.  Intensive Safety Monitoring of Rituximab (Biosimilar Novex® and the Innovator) in Pediatric Patients With Complex Diseases.

Authors:  Natalia Riva; Manuel Molina; Berta L Cornaló; María V Salvador; Andrea Savransky; Silvia Tenembaum; María M Katsicas; Marta Monteverde; Paulo Cáceres Guido; Marcela Rousseau; Raquel Staciuk; Agustín González Correas; Pedro Zubizarreta; Oscar Imventarza; Eduardo Lagomarsino; Eduardo Spitzer; Marcelo Tinelli; Paula Schaiquevich
Journal:  Front Pharmacol       Date:  2022-01-26       Impact factor: 5.810

9.  Acute abdomen due to anaphylactic intestinal edema associated with systematic mastocytosis: a case report.

Authors:  Tomoko Takagishi; Katsuhiko Miki; Shinsaku Imashuku; Katsushige Takagishi
Journal:  Int J Emerg Med       Date:  2022-08-24

10.  Allergic reactions to coronavirus disease 2019 vaccines and addressing vaccine hesitancy: Northwell Health experience.

Authors:  Blanka Kaplan; Sherry Farzan; Gina Coscia; David W Rosenthal; Alissa McInerney; Artemio M Jongco; Punita Ponda; Vincent R Bonagura
Journal:  Ann Allergy Asthma Immunol       Date:  2021-10-24       Impact factor: 6.347

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.